STOCK TITAN
  1. Home
  2. News
  3. NYSE

nyse - nyse STOCK NEWS

Welcome to our dedicated news page for nyse (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on nyse.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect nyse's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of nyse's position in the market.

News
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B at the European Bone Marrow Transplant Annual Meeting, showing higher remission rates and durable complete remission in patients with active relapsed or refractory acute myeloid leukemia. The study revealed a median overall survival of 5.49 months in TP53 positive patients receiving Iomab-B, compared to 1.66 months in those who did not receive it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces positive Phase 3 SIERRA trial results for Iomab-B in patients with TP53 mutation at the European Bone Marrow Transplant Society meeting. The trial showed high statistical significance in achieving durable Complete Remission and 100% BMT access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
clinical trial
-
News
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces a potential breakthrough in targeted radiotherapy conditioning with Iomab-ACT, aiming to replace non-targeted chemotherapy in cell and gene therapies. The collaboration with UT Southwestern for a clinical trial on CAR T-cell therapy shows promising results in reducing toxicities like ICANS and CRS. Iomab-ACT presents a significant market opportunity in the growing field of cellular and gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
clinical trial fda approval
News
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announced that five abstracts have been accepted for presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR. The presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy. Two oral presentations will feature results from the Phase 3 SIERRA trial of Iomab-B, showing improved outcomes for patients with high-risk relapsed/refractory acute myeloid leukemia, including those with a TP53 mutation. The posters will cover topics such as dose-response for durable complete remission and low-dose targeted radioimmunotherapy for patients with relapsed or refractory B-Cell ALL or DLBCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
-
News
HUGOTON ROYALTY TRUST DECLARES NO DECEMBER CASH DISTRIBUTION
Rhea-AI Summary
Argent Trust Company, as Trustee of the Hugoton Royalty Trust (HGTXU), announced the absence of a cash distribution for December 2023 due to excess cost positions on all three of the Trust's conveyances of net profits interests. The Trust's cash reserve was reduced by $106,000 for Trust expenses. XTO Energy advised the Trustee of increased excess costs on properties underlying the Kansas, Oklahoma, and Wyoming net profits interests. Development costs of $9.1 million were charged to the Trust for three non-operated wells in Major County, Oklahoma. The Trustee and XTO Energy will provide updates on the wells. The Trust is in arbitration with XTO Energy over the allocation of production costs related to the Chieftain settlement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
none
-
News
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announces that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual ASH Meeting, highlighting the differentiated capabilities of Iomab-B and Actimab-A in improving overall survival in patients with relapsed or refractory AML with a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
News
HUGOTON ROYALTY TRUST DECLARES NO NOVEMBER CASH DISTRIBUTION
Rhea-AI Summary
HGTXU - Argent Trust Company, as Trustee of the Hugoton Royalty Trust, announced no cash distribution for November 2023 due to excess cost positions. XTO Energy's advice on underlying sales volumes and excess costs in Kansas, Oklahoma, and Wyoming conveyances was detailed. The Trustee and XTO Energy continue to provide updates on non-operated wells and settlement of the Chieftain class action royalty case.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.41%
Tags
none
-
News
High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement
Rhea-AI Summary
Mallinckrodt plc (MNKTQ) expects to complete Irish Examinership and emerge from Chapter 11 in the coming days. The High Court of Ireland confirmed a scheme of arrangement between the Company, its creditors, and shareholders. This satisfies a key condition to the consummation of the Plan. Mallinckrodt intends to emerge from Chapter 11 and cause the Plan to become effective in the coming days. For more information, visit www.MNKrestructuring.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Rhea-AI Summary
Actinium Pharmaceuticals presented data at the Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting, highlighting Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs) in solid tumors. The data showed that Actimab-A reduced cancer patient-derived MDSCs and restored T cell proliferation and effector function. In addition, Actimab-A significantly depleted MDSCs in tumor-bearing humanized mice. The company believes that Actimab-A has the potential to be used in combination with immunotherapy to enhance antitumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
clinical trial
News
Actinium Appoints Lynn Bodarky as Chief Business Officer
Rhea-AI Summary
Actinium Pharmaceuticals has appointed Lynn Bodarky as Chief Business Officer to lead the company's business development, licensing, and collaboration activities. Ms. Bodarky brings over 25 years of experience in business development and licensing, having executed transactions totaling over $5 billion in value across oncology, autoimmune, and neurological indications. Actinium is a leader in the development of targeted radiotherapies, with a pipeline of highly differentiated therapies and expertise in alpha-emitter payload Actinium-225. The company has positive Phase 3 data for Iomab-B, a CRADA with the NCI, an NIH grant for Iomab-ACT, and novel preclinical solid tumor data. Actinium aims to leverage Ms. Bodarky's extensive experience to bring their radiotherapeutics to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
management
Stock NYSE logo
nyse

NYSE:NYSE

NYSE Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NYSE Stock Data